figures ?, page-16

GlaxoSmithKline 2008 figs….

Smoking Cessation Products - £299m Sales (~$530m AUD) (% of this would be patches)
Cold sore franchise - £89m Sales (~$160m AUD)

Also, I think the below product is a competitor to OBJ’s BreatheAssist (OBJ’s product supposedly increases airflow by 36% compared to BreatheRight)

BreatheRight - £81m Sales (~$144m AUD)


They also listed some competitors which may be of interest to some readers….(or in OBJ's case potential clients)
• Abbott Laboratories
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Roche Holdings
• Sanofi-Aventis
• Schering-Plough
• Wyeth


Does anyone have any idea what type of royalty % OBJ could well achieve if all goes to plan ?